LORRAINE RUSCH, PH.D.
Dr. Rusch is a highly experienced drug development scientist and executive, specializing in early clinical research and development services. She has significant drug development expertise from the biotechnology industry and is a leader in the contract research organization sector, known for expanding research capabilities and creating unique service offerings to the biopharma industry.
Randy Barnett is both an Attorney and a Certified Public Accountant (CPA), having practiced law in High Point and Laurinburg, NC, as well as holding financial positions at various organizations in North Carolina.
EXECUTIVE VP OF CORPORATE DEVELOPMENT
Doug Copeland is a business executive with extensive experience in a range of businesses in health care and non-healthcare fields. He has served as vice president of a hospital system and in a leadership role in a number of other businesses and organizations.
Dr. Nuñez is the Medical Director and Principal Investigator at High Point Clinical Trials Center. She has over 20 years of clinical research experience and has conducted over 450 trials in both early and late phase.
Dr. Austin, a residency trained and board certified emergency physician, holds the interests of subjects in the highest standing, particularly with regard to the provision of safety and quality of care in both acute and non-acute situations. When not leading clinical trial work at HPCTC, he is working on community outreach programs in the High Point region.
Dr. Pearson is a residency trained and board certified Emergency Medicine physician (ABEM) who also is fellowship trained in Undersea & Hyperbaric Medicine with Wound Care specialty (UHMS). He has conducted clinical research in vasculopathy wound management and has been involved in Traumatic Brain Injury (TBI) studies. When he is not working at HPCTC you will find Dr. Pearson providing emergency medical care in rural hospitals in North Carolina.
ASSOCIATE DIRECTOR CLINICAL OPERATIONS
Ben is a native of the High Point area and has focused his career in clinical research at HPC since joining the clinic in 2011. Ben has learned the clinic from “the ground up” by working in each of the departments learning the intricacies of clinical research.
Dr. Adnan Mjalli, an internationally recognized entrepreneur in drug discovery and development of new medicines, is the founder of TransTech Pharma and High Point Pharmaceuticals. Both companies are drug discovery, development and commercialization companies now under vTv Therapeutics, High Point Clinical Trials Center (HPCTC), a clinical trials research and development center that conducts human clinical trials and PharmaCore, a drug manufacturing company.
Dr. Mjalli served as Chairman and CEO of TransTech Pharma from December 1998-April 2014. He currently severs as CEO of High Point Clinical Trials Center and Chairman of PharmaCore. Dr. Mjalli obtained his Ph.D. in Medicinal Chemistry in 1989 from the University of Exeter, UK. His postdoctoral work was carried out at the University of Rochester. Dr.Mjalli has held various positions of increasing responsibility in research and senior management at several pharmaceutical and biotechnology companies including Merck & Co., Inc. and Ontogen Corporation. He is the author of more than 40 scientific papers, four book chapters and an inventor on more than 700 patents and patent applications. Dr. Mjalli served on the Board of Directors of Siga Technologies, the North Carolina Biotechnology Center, the Guilford Technology Community College (GTCC) Board, and the High Point Economic Development Corporation.
Currently, Dr. Mjalli serves on the High Point University Board, The Foundation Board of GTCC, High Point Chamber of Commerce, the Arab American University, the American Task Force on Palestine, the America-Mideast Educational and Training Service (AMIDEAST), a member of the American Chemical Society, an honorary fellow of the Islamic World Academy of Sciences, and an honorary member of the Palestine Academy of Science and Technology. Dr. Mjalli has raised hundreds of millions of dollars for his companies listed above. He has also structured, negotiated, and concluded an excess of a dozen multibillion dollar deals with major global pharmaceutical companies.